ATC Group: N06B Psychostimulants, agents used for ADHD and nootropics

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06B in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06B Psychostimulants, agents used for ADHD and nootropics

Group N06B contents

Code Title
N06BA Centrally acting sympathomimetics
N06BC Xanthine derivatives
N06BX Other psychostimulants and nootropics

Active ingredients in N06B

Active Ingredient Description
Adrafinil

Adrafinil is a mild central nervous system stimulating drug typically employed to relieve excessive sleepiness and inattention in geriatric patients. It is also been used off-label to prevent fatigue or falling asleep for extended periods of time. Adrafinil is metabolized to modafinil.

Amfetamine

Amphetamine is a potent central nervous system (CNS) stimulant that is used in the treatment of attention deficit hyperactivity disorder (ADHD), narcolepsy, and obesity. Amphetamine properly refers to a specific chemical, the racemic free base, which is equal parts of the two enantiomers, levoamphetamine and dextroamphetamine, in their pure amine forms. Historically, it has been used to treat nasal congestion and depression. Amphetamine is also used as an athletic performance enhancer and cognitive enhancer, and recreationally as an aphrodisiac and euphoriant.

Aniracetam

Aniracetam is a member of pyrrolidin-2-ones and a N-acylpyrrolidine. It is a compound with anti-depressive properties used as a mental performance enhancer.

Armodafinil

Armodafinil is an indirect dopamine receptor agonist; both armodafinil and modafinil bind in vitro to the dopamine transporter and inhibit dopamine reuptake. Armodafinil (R-modafinil) has pharmacological properties similar to those of modafinil (a mixture of R- and S-modafinil), to the extent tested in animal and in vitro studies.

Atomoxetine

Atomoxetine is a highly selective and potent inhibitor of the pre-synaptic noradrenaline transporter, its presumed mechanism of action, without directly affecting the serotonin or dopamine transporters.

Caffeine

Caffeine is structurally related to the methylxanthines theophylline and theobromine. Caffeine’s main action is as a CNS stimulant.

Citicoline

Citicoline stimulates the biosynthesis of structural phospholipids of the neuronal membrane. Citicoline, through this action, improves the function of the membrane mechanisms, such as the functioning of the ionic exchange pumps and receptors inserted in the latter, the modulation of which is indispensable in the neurotransmission.

Deanol
Dexamfetamine

Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.

Dexmethylphenidate

Dexmethylphenidate is a CNS stimulant. It is the more pharmacologically active d-enantiomer of racemic methylphenidate. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known.

Fencamfamin
Fenetylline
Idebenone

Idebenone is an anti-oxidant assumed to be capable of transferring electrons directly to complex III of the mitochondrial electron transport chain, thereby restoring cellular energy (ATP) generation under experimental conditions of complex I deficiency. Similarly, in LHON idebenone can transfer electrons directly to complex III of the electron transport chain, thereby bypassing complex I which is affected by all three primary mtDNA mutations causing LHON, and restoring cellular ATP generation.

Lisdexamfetamine

Lisdexamfetamine is rapidly absorbed from the gastrointestinal tract and hydrolysed primarily by red blood cells to dexamfetamine, which is responsible for the drug’s activity. Amfetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity.

Meclofenoxate

Meclofenoxate is a cholinergic nootropic with antianoxic effect whether anoxia is provoked by defect or misuse of oxygen. Meclofenoxate improves extraction and utilization of glucose from the brain which allows maintenance of storage of energy for the neuron even in case of O2 deficiency or aging. In elderly patients, meclofenoxate has been shown to improve performance on certain memory tests. Meclofenoxate also increases cellular membrane phospholipids.

Metamfetamine

Methamphetamine is a sympathomimetic amine with CNS stimulant activity. Peripheral actions include elevation of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.

Methylphenidate

Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space.

Modafinil

Modafinil promotes wakefulness in a variety of species, including man. The precise mechanism(s) through which modafinil promotes wakefulness is unknown.

Oxiracetam
Pemoline
Phenibut
Pipradrol
Piracetam

Piracetam’s mode of action in cortical myoclonus is as yet unknown. Piracetam exerts its haemorrheological effects on the platelets, red blood cells, and vessel walls by increasing erythrocyte deformability and by decreasing platelet aggregation, erythrocyte adhesion to vessel walls and capillary vasospasm.

Pirisudanol
Pramiracetam
Pyritinol
Solriamfetol

Solriamfetol is indicated to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Its mechanism of action has not been fully characterised. However, its efficacy could be mediated through its activity as a dopamine and norepinephrine (noradrenaline) reuptake inhibitor (DNRI).

Temgicoluril

Temgicoluril has an effect on the structure of limbic–reticular activity, particularly on hypothalamus emotional zone, as well as on all several basic neuromediator systems – γ aminobutyric acid (GABA), choline, serotonin, and adrenergic activity. It decreases brain norepinephrine levels and increases brain serotonin levels without modulating dopaminergic systems or cholinergic systems. Temgicoluril purportedly has anti-anxiety (anxiolytic) properties. It is also used to aid smoking cessation. In addition, temgicoluril may be useful in the treatment of adult attention-deficit/hyperactivity disorder (ADHD) symptoms.

Vinpocetine

Related product monographs

Title Information Source Document Type  
ADDERALL XR Extended-release capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
AMFEXA Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
Caffeine Citrate 10mg/ml Inj. Sol. Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CONCERTA Extended-release tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
CONTRAMYL Prolonged release tablet Health Products Regulatory Authority (ZA) MPI, Generic
DELMOSART Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
DEXEDRINE SPANSULE Extended-release capsule FDA, National Drug Code (US) MPI, US: SPL/Old
ELVANSE Capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
EQUASYM Modified release capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
FOCALIN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
GENCEBOK Solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
INIR Capsule Health Products Regulatory Authority (ZA) MPI, Generic
MATORIDE XR Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MEDIKINET Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NOOTROPIL Film-coated tablet / Oral solution / Solution for injection Υπουργείο Υγείας (CY) MPI, EU: SmPC
NUVIGIL Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
PEYONA Solution European Medicines Agency (EU) MPI, EU: SmPC
PROVIGIL Tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
RADD Prolonged-release tablet Health Products Regulatory Authority (ZA) MPI, Generic
RAXONE Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
RITALIN Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
RUBIFEN Immediate release tablet, Sustained release tablet Medicines and Medical Devices Safety Authority (NZ) MPI, EU: SmPC
SOMAZINA Oral solution Medicines Authority (MT) MPI, EU: SmPC
STRATTERA Capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
SUNOSI Film‑coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
VYVANSE Capsule / Tablet chewable FDA, National Drug Code (US) MPI, US: SPL/PLR